Literature DB >> 8104617

Bone marrow transplantation in Fanconi's anemia.

E Gluckman1.   

Abstract

Fanconi's anemia (FA), a disease characterized by malformations and progressive pancytopenia, can be successfully cured by allogeneic bone marrow transplantation. Due to the sensitivity of FA cells to alkylating agents, a modified conditioning regimen including low-dose cyclophosphamide (20 mg/kg) and 5 Gy thoracoabdominal irradiation has been used. We report here our experience with bone marrow transplantation in a series of 49 patients. In HLA-identical sibling transplants, the long-term survival was 75%. Results with matched unrelated transplants are limited by the small number of patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104617     DOI: 10.1002/stem.5530110829

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  6 in total

1.  Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?

Authors:  Parinda A Mehta; Chie Emoto; Tsuyoshi Fukuda; Brian Seyboth; Ashley Teusink-Cross; Stella M Davies; Jamie Wilhelm; Kirsten Fuller; Alexander A Vinks; Farid Boulad
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-18       Impact factor: 5.742

2.  Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia.

Authors:  John E Wagner; Mary Eapen; Margaret L MacMillan; Richard E Harris; Ricardo Pasquini; Farid Boulad; Mei-Jie Zhang; Arleen D Auerbach
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

3.  Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia.

Authors:  Parinda A Mehta; Sharon Sauter; Xue Zhang; Stella M Davies; Suzanne I Wells; Kasiani C Myers; Gitika Panicker; Elizabeth R Unger; Melinda Butsch Kovacic
Journal:  Vaccine       Date:  2017-10-16       Impact factor: 3.641

Review 4.  Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation.

Authors:  Andrew C Dietz; Parinda A Mehta; Adrianna Vlachos; Sharon A Savage; Dorine Bresters; Jakub Tolar; Farid Boulad; Jean Hugues Dalle; Carmem Bonfim; Josu de la Fuente; Christine N Duncan; K Scott Baker; Michael A Pulsipher; Jeffrey M Lipton; John E Wagner; Blanche P Alter
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-20       Impact factor: 5.742

5.  Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.

Authors:  Parinda A Mehta; Stella M Davies; Thomas Leemhuis; Kasiani Myers; Nancy A Kernan; Susan E Prockop; Andromachi Scaradavou; Richard J O'Reilly; David A Williams; Leslie Lehmann; Eva Guinan; David Margolis; K Scott Baker; Adam Lane; Farid Boulad
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

6.  Correction of Fanconi Anemia Group C Hematopoietic Stem Cells Following Intrafemoral Gene Transfer.

Authors:  Ouassila Habi; Johanne Girard; Valérie Bourdages; Marie-Chantal Delisle; Madeleine Carreau
Journal:  Anemia       Date:  2010
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.